GlaxoSmithKline (GSK.L) 15-04-20
GlaxoSmithKline (GSK.L) has been in a strong uptrend. Will it continue to set new recent highs?
- Priced at 1590.4p (at time of writing), momentum has been strong.
- Will it come to an end, or is the trend your friend?
- Could this be an opportunity for momentum traders?
- Technical traders should be mindful of new developments, which can have an affect on trends.
- Shares -13% from 12-month highs; +15% from 12 month lows.
Latest News
14 Apr: GlaxoSmithKline announced that it intends to work with rival pharmaceutical company Sanofi to create a Covid-19 vaccine.
06 Apr: GlaxoSmithKline said it will buy a share of Vir Biotechnology for $250m as part of a larger collaboration to create treatment solutions for coronaviruses, including SARS-CoV-2.
01 Apr: DZ Bank reiterates its buy rating on GlaxoSmithKline (GSK) and reduced the target price to 1900p (from 2000p).
01 Apr: GlaxoSmithKline completed the sale of Indian consumer healthcare businesses, including the Horlicks brands, to Unilever.
31 Mar: Oddo reiterates its neutral rating on GlaxoSmithKline (GSK) and reduced the target price to 1530p (from 1830p).
17 Mar: Barclays Capital reiterates its underweight rating on GlaxoSmithKline (GSK) and reduced the target price to 1450p (from 1550p).
03 Mar: Morgan Stanley reiterates its underweight rating on GlaxoSmithKline (GSK) and reduced the target price to 1725p (from 1740p).
Source: Bloomberg, Reuters, Alpha Terminal, FT, DJ Newswires